Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2'3'-cyclic GMP-AMP + ovalbumin + stable nucleic acid lipid particle
- Development stage
- Preclinical
- Lead developer
- King's College London
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intratumoral
01
Overview
2'3'-cyclic GMP-AMP + ovalbumin + stable nucleic acid lipid particle is an experimental therapeutic cancer vaccine platform developed by researchers at King's College London. The formulation consists of an ionizable stable nucleic acid lipid nanoparticle (SNALP) that co-encapsulates mRNA encoding the model antigen ovalbumin (OVA) and the cyclic dinucleotide STING agonist 2'3'-cGAMP. This dual-delivery system is designed to overcome tumor-associated immunosuppression by activating the stimulator of interferon genes (STING) pathway, thereby enhancing dendritic cell maturation, antigen presentation, and the subsequent priming of antigen-specific CD8+ T cells. Preclinical studies presented at AACR 2026 demonstrated that the vaccine can delay tumor onset and induce complete tumor regression in murine melanoma models (B16F10-OVA) when administered via intramuscular or intratumoral routes.
- Other names
- STING-boosted lipid nanoparticle mRNA vaccineSNALP-OVA-cGAMP
02
Targets
STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on 2'3'-cyclic GMP-AMP + ovalbumin + stable nucleic acid lipid particle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2'3'-cyclic GMP-AMP + ovalbumin + stable nucleic acid lipid particle.